The firm founded by Treg cell discoverer Shimon Sakaguchi is building up its US team and refining R&D strategy and manufacturing processes to create an example and global path for other Japanese ventures.

Read more here

Previous
Reflecting on the biotech funding landscape of 2025 and looking ahead to 2026
Next
Miracle babies, antibiotic improv and T-cell tamers: Fierce’s favorite research stories of 2025